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Abstract
Chagas disease is caused by Trypanosoma cruzi infection, being cardiomyopathy the more frequent manifestation. New
chemotherapeutic drugs are needed but there are no good biomarkers for monitoring treatment efficacy. There is growing
evidence linking immune response and metabolism in inflammatory processes and specifically in Chagas disease. Thus,
some metabolites are able to enhance and/or inhibit the immune response. Metabolite levels found in the host during an
ongoing infection could provide valuable information on the pathogenesis and/or identify deregulated metabolic pathway
that can be potential candidates for treatment and being potential specific biomarkers of the disease. To gain more insight
into those aspects in Chagas disease, we performed an unprecedented metabolomic analysis in heart and plasma of mice
infected with T. cruzi. Many metabolic pathways were profoundly affected by T. cruzi infection, such as glucose uptake,
sorbitol pathway, fatty acid and phospholipid synthesis that were increased in heart tissue but decreased in plasma.
Tricarboxylic acid cycle was decreased in heart tissue and plasma whereas reactive oxygen species production and uric acid
formation were also deeply increased in infected hearts suggesting a stressful condition in the heart. While specific
metabolites allantoin, kynurenine and p-cresol sulfate, resulting from nucleotide, tryptophan and phenylalanine/tyrosine
metabolism, respectively, were increased in heart tissue and also in plasma. These results provide new valuable information
on the pathogenesis of acute Chagas disease, unravel several new metabolic pathways susceptible of clinical management
and identify metabolites useful as potential specific biomarkers for monitoring treatment and clinical severity in patients.
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Introduction
Chagas disease, caused by the protozoan parasite Trypanosoma
cruzi, affects approximately 8 million people worldwide [1] and
kills more than 15,000 each year, thus representing a major cause
of morbidity and mortality in endemic countries [2]. Chagasic
cardiomyopathy is the most serious and frequent manifestation in
T. cruzi infected patients in the chronic phase of the disease. Acute
Chagas disease is an often nonspecific and frequently unrecog-
nized condition, but acute infection associated to congenital cases
and oral transmission can have a fatal outcome in humans [3].
Myocarditis, although uncommonly reported and difficult to
diagnose, is uniformly present during acute infection. Moreover,
endomyocardial biopsies taken when patients are diagnosed
during this phase of the disease consistently reveal acute
myocarditis, even if the patient is asymptomatic [4]. The ranges
of acute cardiac pathogenesis are characterized by pericardial
effusion, pericarditis, ventricular enlargement with dysfunction or
congestive heart failure or both [5]. In the chronic phase,
myocardial inflammation associated to mononuclear infiltrate is
a common finding in histological sections, although the spatial
association between parasites and inflammatory infiltrate is
controversial and manifests as heart failure, arrhythmia, heart
block, thromboembolism, stroke, and sudden death. Chronic
Chagasic Cardiomyopathy is characterized by its severity, as well
as by a worse prognosis when compared with other cardiomyop-
athies [6].
T. cruzi has a complex life cycle involving several stages in both
vertebrates and insect vectors. It infects and replicates in
macrophages and cardiomyocytes as well as many other cell types
[2]. However, the pathogenesis is thought to be dependent on an
immune-inflammatory reaction to a low-grade infection [7,8]. To
date no vaccine is available [9] and current drugs have many side
effects [10]. Some chronic asymptomatic patients are currently
treated with those drugs, although its efficacy has not been clearly
demonstrated yet, basically because there is no useful surrogate
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marker for clinical improvement and therapeutic efficacy. In the
meantime, follow up of the treated patients by PCR turned out to
be the only way to guide physicians to deal with the disease
[11,12]. Several studies on biomarkers of cure have been proposed
based on seronegativization of antibodies, lytic antibodies,
hemostatic parameters, natriuretic peptides, recombinant antigens
and proteomic assays [13] but none of them seems to be
particularly sensitive. Thus, new biomarkers are needed to
monitor responses to treatment.
Global metabolomic analysis is a powerful tool to understand
the pathophysiology of parasite infection as well as to identify
biomarkers of disease, as it has been done for dilated cardiomy-
opathy [14]. Thus, identification of metabolic conditions could
provide a deeper knowledge of the pathophysiology and the
immunopathology as well of being of clinical value, since
restoration of those metabolites to basal levels could be beneficial
for the host during acute infection. On the other hand, they could
be also useful as biomarkers. The current paucity of effective
preventive or therapeutic options is another strong motivation for
the study of host-parasite metabolism interplay.
Moreover, metabolic function can clearly affect the activity of
the immune system [15,16,17]. In this regard, in acute T. cruzi
infection there are major immunological changes [18], that in
some cases are linked to the production of amino acid metabolites,
as kynurenine, a product of indolamine 2,3 dioxygenase (IDO)
enzymatic activity from tryptophan, which is supposed to control
parasite growth [19,20]. In addition, the levels of L-arginine,
modulated by Arginase enzymatic activity, deeply affect the
activity of T lymphocytes in experimental T. cruzi infection in
mice [21]. Thus, the knowledge of the metabolic alterations will
help to understand the course of the infection.
Since T. cruzi is able to replicate intracellularly, it will likely
affect infected host cell metabolism. Thus, metabolic changes were
observed in vitro after infection with the parasite in endothelial
cells [22]. In addition, Garg et al performed microarray analysis of
the cardiomyocyte mitochondrial metabolism during in vivo
infection showing deficiencies in mitochondrial oxidative phos-
phorylation-mediated ATP generation that plays an important
role in cardiac homeostasis [23]. More recently, Caradonna et al.
using a genome-scale functional screen identified interconnected
metabolic networks centered around host energy production,
nucleotide metabolism, pteridine biosynthesis, and fatty acid
oxidation as key processes that fuel intracellular T. cruzi growth
in HeLa cells in vitro [24].
However, there are no reports to date on global metabolomic
analysis during in vivo T. cruzi infection. Moreover, metabolite
levels during infection may reflect not only host metabolism but
also the possible contribution of parasite-derived metabolites,
which has never been assessed before. Thus, here we studied the
metabolic profile in heart and plasma from T. cruzi infected mice.
The results unravel many new aspects of metabolic alterations that
can be useful for better understanding the pathogenesis of this
disease and to better control T. cruzi infection as well as showing
the potential of particular metabolites as biomarkers of this disease.
Materials and Methods
Mice and parasites
Young adult (6 to 8-week-old) BALB/c female mice were
transported from Charles River Laboratories and hosted in a
controlled environment. In vivo infections performed with Y T.
cruzi strain (obtained from Dr. John David, Department of
medicine, Harvard Medical School, Boston, Massachusetts,
U.S.A.). Blood trypomastigotes were routinely maintained by
infecting IFNc receptor-deficient mice (129 Ifngrttm1Agt/J) [25]
purifying them from their blood. These mice were a gift from
Manfred Kopf (Max-Planck-Institute for Immunobiology, Frei-
burg). Parasitemia levels were checked every two-three days by
microscopic inspection and counting of parasites in a 5 ml drop of
the tail vein blood as described [26]. Real time qPCR was
performed as described [27].
Ethics statement
This study was carried out in strict accordance with the
European Commission legislation for the protection of animals
used for scientific purposes (Directive 2010/63/EU). Mice were
maintained under pathogen-free conditions at the Centro de
Biologı´a Molecular Severo Ochoa (CSIC-UAM) animal facility.
The protocol for the treatment of the animals was approved by the
‘‘Comite´ de E´tica de Investigacio´n de la Universidad Auto´noma
de Madrid’’, Spain (permit CEI-47-899). Animals had unlimited
access to food and water. They were euthanized in a CO2
chamber and all efforts were made to minimize their suffering.
Experimental design
Global biochemical profiles were determined in methanol
extracts derived from mouse heart tissue and plasma from two
independent experiments including uninfected mice (n = 6) and
mice infected with 2,000 blood trypomastigotes of the Y strain of
T. cruzi (see supplemental experimental information for details),
and sacrificed at 14 (n= 6) and 21 days post-infection (n= 6).
Plasma and heart tissue were elicited. To prevent blood
coagulation, syringes were impregnated with heparin, and plasma
was obtained from the supernatant immediately after centrifuga-
tion of the blood and frozen at 280uC. Hearts were perfused with
Author Summary
Chagas disease, caused by Trypanosoma cruzi, is the most
common cause of cardiomyopathy in Latin America. After
the acute phase myocarditis, the disease becomes asymp-
tomatic, and many years later some patients may develop
Chagas cardiomyopathy. Treatment is available, but causes
side effects. Thus, new drugs are needed, but there are no
good tools to assess treatment efficacy. We performed the
first global metabolomics analysis in heart tissue and
plasma from mice infected with T. cruzi along the infection.
We have identified more than 200 biochemicals (around 2/
3 of total) that significantly differed in heart and 100
(around 1/3) in plasma. Some of those show extremely
marked and highly significant differences. More impor-
tantly, our results unravel many new aspects of metabolic
alterations that can be useful for: a) better understanding
the pathogenesis of this disease; b) provide new clinic-
pathological data of T. cruzi infection that can be
potentially used for a better clinical management of
Chagasic patients; c) define several metabolites as poten-
tial biomarkers of this disease. Thus, our study identifies
common biomarkers of cardiomyopathy but more impor-
tantly specific candidate biomarkers of acute Chagas
Disease Cardiomyopathy, not observed in a clinically
similar disease Idiopathic Dilated Cardiomiopathy. Allan-
toin, kynurenine and p-cresol sulfate, that can be easily
detected in serum, are highly promising candidates. In
summary, we think our results would help to better
understand the pathogenesis and management of the
disease and offer new candidate biomarkers for monitor-
ing the severity of the disease and treatment efficacy.
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10 ml of phosphate buffered saline (PBS) and heparin to remove
blood and immediately frozen at 280uC. Samples were prepared
following instructions from Metabolon (see supplemental experi-
mental information for details).
Parasite DNA quantitative real time PCR
At different days post infection mice were euthanized in a CO2
chamber and blood and heart tissue were collected. Hearts were
perfused with PBS and heparin (1 U/ml) and were minced into
small pieces with a sterile scalpel and DNA was isolated with High
PurePCR Template preparation Kit, Roche. For T. cruzi
detection, we followed the qPCR assay described by [27]. Briefly,
100, 10, 1, 0.1 and 0.01 pg of DNA purified from Y strain
epimastigotes were used to generate the standard curve. Exper-
imental heart tissue qPCR reactions contained 100 ng of genomic
DNA. Murine Tnf gene qPCR reactions were set up for
normalization and expressed as pg Parasite DNA/ng heart tissue
DNA.
Biochemical sample preparation
Samples were prepared following Metabolon’s instructions.
Briefly, heart tissue was defrosted at room temperature (RT) and
cut with sterile surgical blade. Approximately 80 mg of tissue were
weighed and disposed in 2 ml eppendorf tubes. Heart tissue was
heat-inactivated at 50uC for 30 min. 1600 ml of the extraction
methanol solvent A (containing standards resuspended in 80%
HPLC grade Methanol; Sigma Aldrich 494291, CAS 67-56-1)
were added to the sample. Plasma was defrosted at RT. 100 ml of
plasma was transferred to a new tube and any parasites present in
plasma were heat-inactivated at 50uC for 30 min. Then, plasma
was combined with 450 ul of extraction Metabolon solvent B
(containing standards resuspended in 100% HPLC grade Meth-
anol; Sigma Aldrich 494291, CAS 67-56-1). After incubation
for 24 h at RT, samples were stored at 280uC until shipment in
dry ice.
Metabolomic analysis
The extracted samples were split into equal parts for analysis on
the gas chromatography (GC)/mass spectrometry (MS) and liquid
chromatography (LC)/MS platforms. Instrument variability was
determined by calculating the median relative standard deviation
(RSD) for the internal standards that were added to each sample
prior to injection into the mass spectrometers. Overall process
variability was determined by calculating the median RSD for all
endogenous metabolites (i.e., non-instrument standards) present in
100% of the Matrix samples, which are technical replicates of
pooled samples. Values were normalized in terms of raw area
counts (OrigScale). For a single day run, this is equivalent to the
raw data. Each biochemical in OrigScale is rescaled to set the
median equal to 1 and expressed as imputed normalized counts for
each biochemical (ScaledImpData).
Principal components analysis
Principal component analysis (PCA) is a mathematical proce-
dure that uses an orthogonal transformation to convert a set of
observations of possibly correlated variables into a set of values of
linearly uncorrelated variables called principle components. This
transformation is defined in such a way that the first principal
component has the largest possible variance (that is, accounts for
as much of the variability in the data as possible), and the second
component in turn has the highest variance possible under the
constraint that it is orthogonal to (i.e., uncorrelated with) the
preceding component. Thus, data set interpretation is that the
stratification of metabolites by component 1 may have the greatest
contribution to separating the metabolic signature of these samples
followed by component 2.
Statistical analysis
Pair-wise comparisons of data from infected mice respect non-
infected (0 dpi) were performed by Welch’s two sample t-tests
using the program ‘‘R’’ http://cran.r-project.org/.
Figure 1. Parasite burden and mice survival during T. cruzi infection. Parasite burden in blood and survival were monitored every two-three
days as described in material and methods section. (A) Parasitemia. (B) Parasite DNA quantification by qPCR as described in the methods. (C) Mice
survival. (D) Representative heart tissue section stained with H&E showing amastigote nests (white arrow) and mononuclear cell infiltration (black
arrow). (E) Principal component analysis in heart tissue samples. (F) Principal component analysis in plasma samples.
doi:10.1371/journal.pntd.0003337.g001
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Results
Experimental T. cruzi infection
Infection of BALB/c mice with the Y strain of T. cruzi
produced high parasitemia in the second and third week post-
infection (Figure 1A) and no survival was observed by 34 dpi
(Figure 1B). In a simultaneous experiment parasite DNA in heart
tissue increased up to 21 days post-infection (dpi), the last day
analyzed before the end of the experiment (Figure 1C). Besides,
histological analysis of the heart at 21 dpi showed heart damage,
with intense myocarditis and amastigote nests (Figure 1D).
Metabolic changes
We selected samples at 14 dpi and 21 dpi from heart tissue
and plasma 21 dpi for metabolic analysis, corresponding to the
acute phase of infection. We performed a global metabolomic
analysis and we detected a total of 325 compounds of known
identity (named biochemicals) in heart extract and 306
compounds in plasma extract (Table S1). Following log
transformation and imputation with minimum observed values
for each compound, Welch’s two-sample t-test was used to
identify biochemicals that differed significantly between exper-
imental groups. Our analysis identified more than 200
biochemicals (around 2/3) that differed significantly in heart
and 100 (around 1/3) in plasma.
Multiple metabolites were altered upon T. cruzi infection, and
Principal component analysis (PCA) revealed that, in heart tissue,
T. cruzi infection was accompanied by distinct biochemical
changes compared to control animals (Figure 1E). Components
1 and 2 could be decomposed into several metabolite levels that
explained 44.21% and 12.08% of the total variation, respectively.
Thus, samples from control and infected mice at 14 dpi grouped
separately in the analysis, although more heterogeneity was
observed by day 21 post-infection in heart tissue (Figure 1E).
Similarly, in plasma, components 1 and 2 explained 35.71% and
15.40%, respectively, and discriminated biochemicals in control
and infected mice at 21 dpi, despite the greater heterogeneity
observed in this case between individual mice (Figure 1F). PCA
components used for the heart and plasma are shown in
supplementary tables S2 and S3, respectively, which list the
metabolites contributing to the stratification of the PCA profiles.
In this files, the coefficient value of each metabolite for component
1 and component 2 are represented. The larger the positive or
negative coefficients value for a given metabolite, the greater its
contribution to separating the metabolic profiles and thus the
better candidate it may be as a biomarker. We will highlight below
the more relevant changes in several pathways.
Glucose metabolism
Compared to uninfected counterparts, glucose levels were
elevated in heart tissue by days 14 and 21 post-infection
(Figure 2A). This observation likely reflects an increase in glucose
uptake considering glucose levels declined in infected plasma over
time (Figure 2B). This also agrees with the observed increase of the
sorbitol pathway metabolites, sorbitol and fructose, in the heart.
Besides, multiple glycolytic intermediates including glucose-6
phosphate and fructose-6-phosphate and the end products
pyruvate and lactate were also significantly elevated in infected
heart tissue, but not in plasma (Figure 2A and B, respectively). In
contrast, reduced glucose shuttling to the pentose phosphate
pathway (PPP) was observed in response to infection as marked by
lower levels of ribulose and sedoheptulose-7-phosphate. Thus,
infected hearts have increased glycolysis.
Tricarboxylic acid cycle (TCA)
In infected heart tissue, the TCA cycle intermediates,
succinylcarnitine and fumarate decreased (Figure 3A). This TCA
cycle imbalance in the heart may be indicative of decreased
oxidative metabolism, potentially resulting from succinate dehy-
drogenase (SDH) and electron transport complex II dysfunction.
However, all of the TCA cycle metabolites, including succinate,
were diminished in plasma of infected mice (Figure 3B).
Lipid metabolism
Following infection, long chain fatty acids such as palmitate,
stearate and oleate increased in heart tissue, but reduced in the
plasma (Figure 4A and 4B, respectively). Although changes in fatty
acid levels may be indicative of a difference in synthesis,
malonylcarnitine levels were significantly diminished in infected
tissue, suggesting a limited capacity for lipid biogenesis. Instead,
Figure 2. Carbohydrate pathways. (A) Graphs represent the
ScaledImpData of different biochemicals of the glycolytic, sorbitol and
pentose phosphate pathways from heart tissue. (B) Same as in A from
plasma samples. Samples from control uninfected mice are in white
boxes, from mice sacrificed at 14 dpi in light gray boxes and from mice
sacrificed at 21 dpi in dark grey boxes. Statistically significant
differences respect to uninfected mouse samples are denoted, *p#0.05.
doi:10.1371/journal.pntd.0003337.g002
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uptake of lipids from plasma and fatty acid b-oxidation in the
heart tissue may be altered considering that long chain carnitine
conjugate lipids such as palmitoylcarnitine and oleoylcarnitine
were much higher in infected animals and may reflect increased
lipid transport into the mitochondria, as evidenced by lower levels
of carnitine.
Phospholipid metabolism
The phospholipid catabolite glycerophosphorylcholine (GPC)
was elevated in heart tissue after infection (Figure 4C). This may
be indicative of a change in phospholipid dynamics since it was
accompanied by much higher levels of multiple lysolipids such as
1-linoleoylglycerophosphoethanolamine and 1-palmitoleoylglycer-
ophosphocholine that may reflect enhanced hydrolysis of phos-
pholipids or lipid bodies. In contrast, these metabolites were
diminished or unaltered in the plasma of infected animals
(Figure 4D). Additionally, phospholipid precursors as choline,
choline phosphate, ethanolamine, and phosphoethanolamine
especially at late time points also accumulated in infected heart
tissue and may be indicative of an increased capacity for
phospholipid synthesis, and thus very high accumulation of
phospholipids in the heart of infected animals.
Branched chain amino acid metabolism (BCAA)
Heart tissue from T. cruzi infected mice possessed higher levels
of the BCAAs leucine, isoleucine and valine (Figure 5A).
Differences in BCAA levels can reflect changes in their degrada-
tion and utilization. In this sense, the downstream products 2-
methylbutyrylcarnitine, isovalerylcarnitine and alpha-keto acids
(3-methyl-2-oxovalerate and 4-methyl-2-oxopentanoate) were sig-
nificantly elevated in heart. Additionally, BCAA catabolites
including the alpha-keto acids were also increased in plasma
(Figure 5B).
Nucleotide metabolism
Compared to uninfected controls, heart tissue from T. cruzi
infected mice dramatically exhibited much lower levels of multiple
purine nucleotides and related metabolites such as adenine,
inosine, and hypoxanthine being the levels of adenine almost
depleted (Figure 6A). Such metabolites indicate severe alterations
in redox homeostasis. In addition, heme, another product of redox
activity increased 20–30 times in the infected heart (Figure 6B). In
contrast, higher levels of xanthosine, xanthine, urate and allantoin
were found in heart tissue from infected mice (Figure 6A). Similar
to heart tissue, lower levels of inosine and increased allantoin were
found in plasma (Figure 6C). These results may reflect a decrease
in synthesis as supported by lower levels of pentose phosphate
pathway metabolism. However, more likely purine degradation
may be strongly enhanced as evidenced by the great accumulation
of the downstream catabolic products xanthosine, urate, and
allantoin in infected hearts.
Tryptophan metabolism
Tryptophan and some of its metabolites as kynurenine, c-
glycosyltryptophan and 3-indoxyl sulfate were increased in heart
tissue (Figure 7A) as well as kynurenine and c-glycosyltryptophan
in plasma from infected mice (Figure 7B).
p-Cresol sulfate
p-Cresol sulfate is part of the phenylalanine and tyrosine
metabolism, and it was found strongly increased both in heart
tissue and plasma from infected mice (Figure 7C and 7D,
respectively). p-Cresol sulfate is likely a microbial metabolite that
is found in urine and blood and likely derives from secondary
metabolism of p-Cresol.
Discussion
Chagas is a complex disease with acute and chronic phases
showing cardiac alterations. Although, the immunopathogenesis is
relatively well established, there are still several issues poorly
Figure 3. Tricarboxyilic acid cycle. (A) Graphs represent the
ScaledImpData of different biochemicals of the tricarboxyilic acid cycle
from heart tissue samples. (B) Same as in A from plasma samples.
Samples from control uninfected mice are in white boxes, from mice
sacrificed at 14 dpi in light gray boxes and from mice sacrificed at
21 dpi in dark grey boxes. Statistically significant differences respect to
uninfected mouse samples are denoted, *p#0.05.
doi:10.1371/journal.pntd.0003337.g003
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understood. Among those: why a minority of asymptomatic
patients become symptomatic after several years?; and which is the
reason for the different clinical manifestations?. Besides, few drugs
are available to date, which present adverse effects that many
patients cannot tolerate. Thus, new drugs are urgently needed,
and to achieve that, a deeper knowledge of clinical pathophysi-
ology is required. In this respect, metabolomics may help to better
characterize the pathophysiology of the disease as well as to define
new biomarkers.
In an unprecedented study, we performed global metabolomic
analysis in plasma and heart of mice infected with the T. cruzi Y
strain. This parasite strain has been considered reticulotropic by
many authors in the field. However, other authors claim that the
strain might have suffered a change from reticulotropic to
myotropic/cardiotropic through time [28]. In agreement with
the last, in our experimental model it infects cardiomyocytes [29],
produces a characteristic histologic alterations as homogeneous
pancarditis with inflammatory infiltrates along epicardium, a high
epicardial and sub-epicardial inflammation that was homogenous
in auricles and ventricles, myeloid and lymphoid infiltration and
intra-myocardial perivasculitis [30] resembling damage observed
in Chagasic patients [31]. Moreover, Our analysis revealed that
following infection there are many significant biochemical
alterations in heart and plasma of infected animals, which are
much more evident both in number of changes and in fold
variations in the heart, the target organ of T. cruzi infection. Our
results have identified more than 200 biochemicals (around 2/3)
that differed significantly in heart and 100 (around 1/3) in plasma.
Some of those showed extremely marked and highly significant
differences. More importantly, our results unravel many new
aspects of metabolic alterations that can be useful for better
understanding the pathogenesis of this disease and to better
control T. cruzi infection as well as showing the potential of
particular metabolites as biomarkers. Our study identifies common
biomarkers of cardiomyopathy but more importantly specific
candidate biomarkers of acute Chagas Disease Cardiomyopathy,
not observed in a clinically similar disease as Idiopathic Dilated
Cardiomyopathy.
Alterations include amino acid metabolism, glucose utilization,
the TCA cycle, nucleotide catabolism, and membrane lipid
Figure 4. Fatty acid and phospholipid metabolism. (A) Graphs represent the ScaledImpData of different biochemicals of fatty acid metabolism
from heart tissue. (B) Same as in A from plasma samples. (C) Same as in A of different biochemicals of phospholipid metabolism from heart tissue
samples. (D) Same as in C from plasma samples. Samples from control uninfected mice are in white boxes, from mice sacrificed at 14 dpi in light gray
boxes and from mice sacrificed at 21 dpi in dark grey boxes. Statistically significant differences respect to uninfected mouse samples are denoted,
*p#0.05.
doi:10.1371/journal.pntd.0003337.g004
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pathways. Glucose can be utilized to support a variety of
physiological processes including energy generation, fatty acid
synthesis, and nucleotide biogenesis. Our results show that
compared to control uninfected animals, glucose levels were
elevated in heart tissue by days 14 and 21 post-infection. This
observation may reflect an increase in glucose uptake considering
that glucose levels declined in infected plasma over time.
Furthermore, the accumulation of the sorbitol pathway metabo-
lites (sorbitol and fructose) in the heart, but not in plasma, may be
an indication of enhanced glucose uptake since excess glucose is
often reduced to sorbitol by aldose reductase. Consequently,
higher levels of sorbitol can contribute to the generation of
advanced glycation end products (AGE) that have been associated
with the development of heart failure in other diseases [32]. In
addition, multiple glycolytic intermediates including glucose-6
phosphate and fructose-6-phosphate and the end products lactate
and pyruvate were significantly elevated in infected heart tissue
and may be indicative of increased glycolysis. In this regard,
accelerated rates of glycolysis can be indicative of hypertrophy of
the heart [33] that accompanies many forms of heart dysfunction,
a hallmark of Chagas disease [34]. Thus, these alterations in
glycolytic metabolism may be associated with increased cardiac
stress in T. cruzi infected hearts and require further investigation.
In contrast, reduced glucose shuttling to the pentose phosphate
pathway (PPP) was observed in response to infection, which is
required for the biogenesis of nucleotides and the regeneration of
NADPH necessary for glutathione reduction and anabolic
reactions. Thus, diminished PPP metabolism may restrict the
biosynthetic capacity of the heart and contribute to altered redox
homeostasis.
Altered glycolytic metabolism suggested that the TCA cycle
may also differ following T. cruzi infection. In fact, in T. cruzi
infected mice an imbalanced TCA cycle in the heart is likely
indicative of decreased oxidative metabolism, potentially resulting
from succinate dehydrogenase (SDH) and electron transport
complex II dysfunction. This would be in agreement with previous
studies where chagasic hearts showed mitochondrial respiratory
chain impairment [35]. Since the heart has perpetually high
energy demands related to the maintenance of processes such as
ion transport, calcium homeostasis, and sarcomeric function, the
fact that TCA cycle mediated oxidative metabolism may be
diminished following infection may ultimately induce metabolic
stress in cardiac tissue. In this respect, disruption of the Krebs
cycle is often implicated in energetic imbalances characteristic of
myocardial ischemia [36,37]. Alternatively, those selective differ-
ences in succinate may be explained by interference of those
metabolites by T. cruzi metabolism due to fumarate reductase and
succinate dehydrogenase enzymatic activities expressed by this
parasite [38].
In addition to protein synthesis, branched chain amino acids
(BCAA) can be degraded to replenish the TCA cycle and facilitate
fatty acid synthesis. Furthermore, diverse injuries and heart
diseases are reported to increase consumption of BCAAs. In
agreement, heart tissue from T. cruzi infected mice possessed
higher levels of the BCAAs isoleucine, leucine and valine.
Differences in BCAA levels can reflect changes in degradation
and amino acid utilization. Additionally, multiple BCAA catab-
olites including the alpha-keto acids 3-methyl-2-oxovalerate and 4-
methyl-2-oxopentanoate and the downstream products 2-methyl-
butyrylcarnitine and isovalerylcarnitine were significantly elevated
in these tissues as well as plasma. Thus, these observations may
reflect an increase in amino acid and muscle turnover following
infection.
Fatty acids are a critical source of energy for mitochondrial
oxidation and cellular ATP generation. Following infection, long
chain fatty acids such as palmitate, stearate, and oleate were
elevated in heart tissue, but reduced in plasma. Although changes
in fatty acid levels may be indicative of a difference in synthesis,
malonylcarnitine levels were significantly diminished in infected
tissue, suggesting a limited capacity for lipid synthesis. On the
contrary, long chain carnitine conjugate lipids such as palmitoyl-
carnitine and oleoylcarnitine were high suggesting that lipid
transport into the mitochondria may be increased. Collectively,
these observations suggest that lipid accumulation due to fatty acid
uptake in this tissue may not promote intracellular parasite
replication by enhancing lipid oxidation as described [24], but
instead, by producing a great deal of host cell lipid bodies, a
characteristic trait in T. cruzi infection [39]. Interestingly, cardiac
lipotoxicity results from elevated palmitoly-L-carnitine [40], which
we found elevated in hearts of T. cruzi infected mice. On the
contrary, propionyl-carnitine is considered a cardiac protector
[41] and we found it decreased in infected heart.
Phospholipids are essential components of the membrane lipid
bilayer. In comparison to control heart tissue, the phospholipid
catabolite glycerophosphorylcholine (GPC) was elevated following
infection. It may be indicative of a change in phospholipid
dynamics and were accompanied by strikingly higher levels of
multiple lysolipids such as 1-linoleoylglycerophosphoethanolamine
and 1-palmitoleoylglycerophosphocholine that may reflect en-
hanced hydrolysis of phospholipids or production of lipid
bodies. Additionally, the phospholipid precursors choline, choline
Figure 5. Branched chain amino acid metabolism. (A) Graphs
represent the ScaledImpData of different biochemicals of the branched
chain amino acid metabolism from heart tissue samples. (B) Same as in
A from plasma samples. Samples from control uninfected mice are in
white boxes, from mice sacrificed at 14 dpi in light gray boxes and from
mice sacrificed at 21 dpi in dark grey boxes. Statistically significant
differences respect to uninfected mouse samples are denoted, *p#0.05.
doi:10.1371/journal.pntd.0003337.g005
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phosphate, ethanolamine, and phosphoethanolamine also accu-
mulated in infected heart tissue and may be indicative of an
increased capacity for phospholipid synthesis. Differences in these
metabolites may reflect tissue remodeling during infection.
Noteworthy, heart tissue from T. cruzi infected mice was almost
depleted of adenine and had much lower levels of purine
nucleotides and metabolites such as adenosine, guanosine, inosine,
and hypoxanthine, compared to uninfected controls. Lower levels
of these metabolites may reflect a decrease in synthesis as
supported by lower levels of pentose phosphate pathway metab-
olism. But more likely, purine degradation may be enhanced as
evidenced by a strong accumulation of the downstream catabolic
products xanthosine, xanthine, urate, and allantoin in infected
hearts. Differences in the levels of these metabolites may also
reflect a change in redox homeostasis since the generation of
xanthine and urate are accompanied by the production of
hydrogen peroxide (H2O2). Thus, differences in purine metabo-
lism may contribute to altered redox homeostasis in cardiac tissue.
In addition, it has been described that the parasite scavenges
purines and pteridine for amastigote replication in HeLa cells [24].
Thus, the decreased levels of adenine observed in heart tissue may
reflect both phenomena: decreased synthesis and parasite utiliza-
tion.
Interestingly, xantine oxidase (XOS) the enzyme responsible for
reactive oxygen species (ROS) generation has been considered
responsible for cardiac dysfunction in T. cruzi infection [42].
Thus, allopurinol, a xanthine oxidase inhibitor, is being considered
for treating Chagasic patients [43]. Inhibition of ROS generation
ameliorates myocarditis during Chagas disease, although parasite
burden in the heart was not significantly decreased [44].
Interestingly, the effect of ROS inhibition seems to be related
with the levels of metabolites as substrates of immune-related
Figure 6. Nucleotide metabolism. (A) Graphs represent the ScaledImpData of different biochemicals of the nucleotide metabolism from heart
tissue samples. (B) Same as in A from plasma samples. Samples from control uninfected mice are in white boxes, from mice sacrificed at 14 dpi in
light gray boxes and from mice sacrificed at 21 dpi in dark grey boxes. Statistically significant differences respect to uninfected mouse samples are
denoted, *p#0.05.
doi:10.1371/journal.pntd.0003337.g006
Figure 7. Tryptophan, phenylalanine and tyrosine metabolism.
(A) Graphs represent the ScaledImpData of different biochemicals of the
tryptophan metabolism from heart tissue samples. (B) Same as in A
from plasma samples (C) A Graphs represent the ScaledImpData of
different biochemicals of the phenylalanine and tyrosine metabolism
from heart tissue samples. (D) Same as in C from plasma samples.
Samples from control uninfected mice are in white boxes, from mice
sacrificed at 14 dpi in light gray boxes and from mice sacrificed at
21 dpi in dark grey boxes. Statistically significant differences respect to
uninfected mouse samples are denoted, *p#0.05.
doi:10.1371/journal.pntd.0003337.g007
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enzymes and thus their imbalances can be targeted to combat
infectious diseases.
Besides, the fact that uric acid is so strongly elevated and
adenine so depleted may indicate that ROS production in the
heart should be very high (Figure 6A). ROS also increase the
ability of T. cruzi to replicate intracellularly [45]. Uric acid is
linked to several cardiovascular diseases [46,47,48], although there
is still discrepancy on whether it is really the cause or the effect of
the disease [49]. The increase in uric acid is also associated to
elevated fructose [50], also shown in our analysis. Uric acid is able
to activate inflammasome NLRP3, being a danger signal in many
pathological processes and in inflammation. Higher signaling
through NLRP3 has been recently related to adverse outcome in
other forms of cardiac dysfunction as idiopathic dilated cardio-
myopathy [51]. However, in apparent contrast, it has been
recently demonstrated a protective role of NLRP3 inflammasome
in the control of T.cruzi infection through caspase-1-dependente
IL-1R-independent nitric oxide (NO) production [52]. Thus, it
would be worth testing the role of NLRP3 in Chagas disease
cardiomyopathy and not only relative to infection.
In addition, Heme, a product involved in redox homeostasis,
was increased in infected heart, and is also able to increase T. cruzi
growth [53]. Increased heme levels are found in failing hearts [54]
associated to ROS production. In this regard, it is also worth
mentioning that allopurinol, that inhibits XOS, has been used
effectively against T. cruzi in mouse models [43,55] and also to
prevent cardiovascular dysfunction (CVD) [48].
Lysoglycerol-phosphocholines, that increased very significantly
in T. cruzi infected heart, may also contribute to immunosup-
pression associated to Chagas disease [56], since they inhibit T-cell
proliferation in response to activation and induce apoptosis [57].
Kynurenine is not usually found in heart tissue, and acts as an
endothelium-derived relaxing factor produced during inflamma-
tion [58]. It can also control dendritic cell immunogenicity [59].
Notably, this metabolite has been implicated in resistance to T.
cruzi infection [19,20]. Furthermore, the serum levels of IDO
enzymatic activity in Chagas disease symptomatic patients
decrease with therapeutic treatment [60]. Since, IDO activity is
often elevated in response to inflammatory cytokines such as
TNFa and IFNc, elevated in cardiac patients [12], these findings
may reflect immune cell activation in response to T. cruzi
infection.
p-Cresol sulfate and indoxyl sulfate are considered uremic
toxins [61]. Although they are generally associated to dialysis
disturbances they have an emerging role in cardiovascular disease
and mortality in renal patients. Serum p-Cresol sulfate predicts
cardiovascular disease and mortality in elderly hemodialysis
patients [62]. In patients with chronic renal failure p-cresol
sulphate accumulation in plasma is due to renal dysfunction and
cause endothelial dysfunction increasing the cardiovascular risk
[63]. We found it highly increased in heart tissue as well as serum
of infected mice. The levels of p-cresol sulphate can be also
predictive of clinical outcome. Our work, if confirmed in Chagas
disease patients, may suggest that p-cresol sulphate could be useful
a marker of T. cruzi infection and further studies are needed to
check if it also correlates with disease outcome.
Recently, a global metabolomic analysis in an experimental
hamster model of idiopathic dilated cardiomyopathy (DCM) has
been described [14]. By comparison with our data some specific
biomarkers, and by extension pathogenic mechanism(s), can be
inferred, that can help to distinguish among those clinically similar
but etiologically distinct dilated cardiomyopathies. In that study,
only 180 metabolites were detected and variations were found in
62 of them. Their results suggest that the glycolysis and the TCA
cycle energy pathways are attenuated in cardiac tissue during the
symptomatic phase. In contrast, hearts from T. cruzi infected mice
have increased glycolysis, despite having the TCA cycle decreased.
Similar to our results they observed increased oxidative stress in
the DCM. Thus, the rest of alterations we found can be considered
specific, so far, of cardiomyopathy associated to T. cruzi infection.
Among those, much higher lipid (and specially phospholipids)
accumulation in T. cruzi infected hearts as well as stronger
depletion of adenine and increase in allantoin and uric acid.
Previous studies on metabolic alterations caused by T. cruzi
infection were based only on host enzymatic expression in vitro
[24]. Thus our work greatly expands those results by detecting
their metabolites in vivo in a mouse model of infection. Our
findings suggest that T. cruzi infection disrupts multiple biochem-
ical pathways in heart tissue that may ultimately contribute to
cardiac failure. In particular, increased glycolysis and decreased
oxidative metabolism may predispose heart muscle to energetic
imbalances characteristic of heart failure [64]. Furthermore,
altered glucose utilization may limit the anabolic capacity of the
heart and therefore the ability to repair damaged tissue and to
detoxify free radicals. Consequently, evidence of altered redox
homeostasis, inflammation, and tissue remodeling were observed
in response to infection.
In summary, we have found many metabolic alterations in
experimental acute Chagas disease. Many of these suggest a
stressful condition in the heart such as: a) increased glycolysis, b)
respiratory chain impairment, c) lipid accumulation, d) ROS
production and uric acid formation. All of those could be related
with heart hypertrophy. Noteworthy, some of those metabolites
have much stronger variations than reported in other cardiac
pathologies. Probably more interestingly, we found elevated p-
cresol sulfate, which is associated to infections, and kynurenine
and allantoin in serum that, either individually or in combination,
may be specific biomarkers in this disease. Moreover, p-cresol
sulfate, kynurenine and allantoin presented very high positive
coefficients in the PCA analysis in plasma reinforcing its value as
possible biomarkers. Very importantly, in the evaluation of new
drugs against Chagas disease, a biomarker of cardiac function
recovery is urgently needed to assess the efficacy of new treatments
in the clinic-pathological symptoms and not only for determining
parasitological cure. Despite that our study spans only the acute
Chagas disease, taking into account that acute and chronic phases
share some similarities, the possibility that any of the candidate
biomarkers may apply to the chronic phase cannot be excluded.
Thus, future studies may benefit from examining metabolic
differences induced by acute versus chronic infection to determine
the long-term risk factors associated with T. cruzi infection, as well
as exploring the usefulness of the ones described here as
biomarkers of clinical improvement.
Supporting Information
Table S1 Summary of the significantly altered bio-
chemicals. 325 biochemical were identified in heart extracts and
306 in plasma extract. Following log transformation and
imputation with minimum observed values for each compound,
Welch’s two-sample t-test was used to identify biochemicals that
differed significantly between experimental groups. Biochemicals
that achieved statistical significance (p#0.05), as well as those
approaching significance (0.05,p,0.10), is shown. Increased
levels of biochemicals are in red and decreased levels in green.
(DOCX)
Table S2 Contribution of the heart tissue individual
biochemicals to the Principal components analysis
Global Metabolomics in Trypanosoma cruzi Infection
PLOS Neglected Tropical Diseases | www.plosntds.org 9 November 2014 | Volume 8 | Issue 11 | e3337
(PCA). List of the calculated coefficients of heart tissue
biochemicals ordered from higher to lower. The higher positive
and negative coefficients are the ones that have more contribution
for the PCA analysis. Component 1 may have the greatest
contribution to separating the metabolic signature followed by
component 2. Plasma candidate biomarkers as p-cresol sulphate,
kynurenine and allantoin, which increase with the infection are
highlighted.
(DOCX)
Table S3 Contribution of the plasma individual bio-
chemicals to the Principal components analysis (PCA).
List of the calculated coefficients of heart tissue biochemicals
ordered from higher to lower. The higher positive and negative
coefficients are the ones that have more contribution for the PCA
analysis. Component 1 may have the greatest contribution to
separating the metabolic signature followed by component 2.
Plasma candidate biomarkers as p-cresol sulphate, kynurenine and
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